Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001

The platelet inhibitory effects of the Phase 3 anticancer agent and nitric oxide (NO) donor, RRx‐001, (1‐bromoacetyl‐3,3‐dinitroazetidine) were examined ex vivo and compared with the diazeniumdiolate NO donor, diethylenetriamine NONOate (DETA‐NONOate), which spontaneously releases nitric oxide in aq...

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Oronsky, Neil, Cabrales, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156345/
https://www.ncbi.nlm.nih.gov/pubmed/30010241
http://dx.doi.org/10.1111/jcmm.13791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156345/
https://www.ncbi.nlm.nih.gov/pubmed/30010241
http://dx.doi.org/10.1111/jcmm.13791

Ejemplares similares